[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-rhinosinusitis-crs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-rhinosinusitis-crs":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,46,75,99,127,154,176,203,232,255,279,307,336,361,384,414,435],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100645278","cognitive-and-immunologic-profiles-of-patients-with-olfactory-dysfunction-after-smell-training-100645278",false,"NCT07681973","Cognitive and Immunologic Profiles of Patients With Olfactory Dysfunction After Smell Training","CIPOD","Inclusion Criteria:\n\n* Age less than 18 years-old\n* Present to rhinology clinic with CRS with nasal polyps\n* Sense of smell loss for any reason (other than trauma or tumor)\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years of age\n* Individuals with unilateral nasal polyps\n* Autoimmune diseases\n* Ciliary disorders\n* Cystic fibrosis\n* Smell loss due to tumors or trauma",true,"ALL","18 Years",{"count":20,"type":21},52,"ESTIMATED","INTERVENTIONAL",[24],"NA","A research study to assess the baseline olfactory function, mental health status, clinical severity, and immunological profile in patients with smell loss. The impact of a 3-month olfactory training program on smell function, immunological changes, and mental health in patients with smell loss will be evaluated.\n\nThe primary purpose of this study is to investigate tissue and blood samples to identify molecules that may be related to smell loss, ultimately aiming to develop future treatments for this condition and correlate with cognition.",[27,28],"Smell Loss","Chronic Rhinosinusitis (CRS)",[27,30,31,32],"Chronic Rhinosinusitis","Nasal Polyps","CRSwNP","RECRUITING","2026-06-26",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2025-12-09",{"date":41,"type":21},"2027-03-31",{"name":43,"class":44},"The Cleveland Clinic","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100638123","active-vs-passive-vr-during-office-based-ent-procedures-100638123","NCT07599826","Active vs. Passive VR During Office-based ENT Procedures","Active vs. Passive Virtual Reality for Reducing Pain and Anxiety During Office-based ENT Procedures","Inclusion Criteria Active and Passive VR:\n\n* Individuals 18 years old and older are included\n* Individuals undergoing the following common office-based ENT procedures: turbinate reduction, nasal debridement, balloon sinuplasty, radiofrequency ablation (Rhineaer\u002FVivaer), nasal polypectomy, eustachian tube dilation, vocal fold injection, or subglottic steroid injection\n* Able to consent\n* English speaking\n\nExclusion Criteria Active VR:\n\n* History of neurologic or seizure disorder, developmental delay, uncorrected visual impairment, motion sickness, vertigo, or inability to use a handheld controller\n* Any records flagged \"break the glass\" or \"research opt out.\"\n\nExclusion Criteria Passive VR:\n\n* History of neurologic or seizure disorder, developmental delay, uncorrected visual impairment, motion sickness, or vertigo\n* Any records flagged \"break the glass\" or \"research opt out.\"",{"count":54,"type":21},132,[24],"The purpose of this research is to evaluate whether active virtual reality reduces pain and anxiety more effectively than passive virtual reality during office-based ENT procedures. The main procedures include exposure to virtual reality (passive calming scenery or interactive puzzle game) via Paperplane Therapeutics software with VR headset or glasses during common in-office ENT procedures, participant self-report surveys (GAD-7, PHQ-9, PEG, VAS, SUDS, Likert, experience questions), and physician post-procedure survey. The study will enroll individuals 18 years or older who are scheduled to undergo common office-based ENT procedures (turbinate reduction, nasal debridement, balloon sinuplasty, radiofrequency ablation, nasal polypectomy, eustachian tube dilation, vocal fold injection, or subglottic steroid injection) at Cedars Sinai.",[58,59,28,60,61,62,63,64],"Pain","Anxiety","Nasal Obstruction","Nasal Polyp","Eustachian Tube Dysfunction","Dysphonia","Subglottic Stenosis (SGS)","NOT_YET_RECRUITING","2026-05-14",{"date":68,"type":37},"2026-05-20",{"date":70,"type":21},"2026-06",{"date":72,"type":21},"2027-12",{"name":74,"class":44},"Cedars-Sinai Medical Center",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":45},"100634976","propel-drug-eluting-sinus-implant-family-ibuki-cohort-100634976","NCT07546682","Propel Drug-Eluting Sinus Implant Family IBUKI Cohort","Inclusion Criteria:\n\n* Patient or legally authorized representative (LAR) provides authorization and\u002For consent per institution and geographical requirements\n\n  * Patient has, or is intended to receive or be treated with, an eligible Medtronic product\n  * Patient is consented within the enrollment window of the therapy received, as applicable\n  * Patient has a confirmed diagnosis of CRS, and is indicated for FESS per Japan standard practice\n  * FESS is successfully completed without the occurrence of major\u002Fsignificant complications that may confound study results\n  * Successful placement of 2 to 4 corticosteroid-eluting implants in the ethmoid or frontal sinus (1 implant per sinus) in accordance with implant IFUs\n  * NOVAPAK is the only hemostatic packing material placed bilaterally in ethmoid sinuses\n\nExclusion Criteria:\n\n* Patient has clinical evidence of disease or a condition expected to compromise survival or ability to complete follow-up assessments through Month 6 (end of study)\n\n  * Participation is excluded by local law\n  * Patient is currently enrolled in, or plans to enroll in, any concurrent study that may confound the PSR results (i.e., no required intervention that could affect interpretation of all-around product safety and\u002For effectiveness)\n  * Patient has received biologic medication approved for the treatment of CRSwNP (e.g., dupilumab, mepolizumab) in ≤ 12 weeks prior to the baseline\u002Fprocedure visit\n  * Patient is contraindicated in accordance with IFUs of PROPEL family implants and\u002For NOVAPAK",{"count":82,"type":21},100,"6 Months","OBSERVATIONAL","To confirm clinical safety and performance for the PROPEL family of products when used according to IFUs and standard of care in Japan.",[28],[88],"Chronic Rhinosinusitis, corticosteroid-eluting sinus implants, 22- item sinonasal outcome test","2026-04-16",{"date":91,"type":37},"2026-04-23",{"date":93,"type":21},"2026-04",{"date":95,"type":21},"2027-08",{"name":97,"class":98},"Medtronic","INDUSTRY",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":45},"100622688","the-efficacy-of-olfactory-cleft-steroid-drops-in-patients-with-crs-with-olfactory-cleft-obstruction-100622688","NCT07386873","The Efficacy of Olfactory Cleft Steroid Drops in Patients With CRS With Olfactory Cleft Obstruction","Randomized Controlled Trial on the Efficacy of Olfactory Cleft Steroid Drops in Patients With Chronic Rhinosinusitis With Olfactory Cleft Obstruction","Inclusion Criteria:\n\n1. Prospective enrollment of otolaryngology clinic patients aged 18-65 years with olfactory dysfunction. Diagnosis of chronic rhinosinusitis-related olfactory dysfunction is based on the EPOS 2020 guidelines. Participants must demonstrate olfactory impairment via Sniffin' Sticks testing, with TDI scores (sum of Threshold, Discrimination, and Identification) meeting:(1) Hyposmia: 16 \\\u003C TDI \\\u003C 30.75; (2) 3.Anosmia: TDI \\\u003C 15.\n2. Sinus CT scans confirming obstruction in the olfactory cleft region.\n3. Willingness to participate and signed informed consent.\n\nExclusion Criteria:\n\n1. Use of systemic corticosteroids within 4 weeks or intranasal steroids within 2 weeks prior to enrollment.\n2. Severe nasal septum deviation, nasal tumors, acute upper respiratory infections, or uncontrolled allergic rhinitis.\n3. Severe cardiovascular disease, hepatic\u002Frenal insufficiency, uncontrolled diabetes, or immune system disorders.\n4. Current or planned pregnancy.\n5. Investigator-determined inability to comply with study requirements (e.g., memory\u002Fbehavioral disorders, depression, heavy alcohol use, prior non-compliance).","65 Years",{"count":108,"type":21},54,[24],"This study aims to compare the efficacy of steroid nasal drops targeting the olfactory cleft versus traditional intranasal steroid sprays in improving olfactory function in patients with chronic rhinosinusitis (CRS) with olfactory cleft obstruction. The main questions this clinical trial aims to answer are:\n\n1. Efficacy Comparison: Is olfactory improvement greater with olfactory cleft-targeted steroid nasal drops compared to standard nasal steroid sprays in CRS patients?\n2. Mechanism Exploration: How do changes in inflammatory markers, obstruction severity, and olfactory test results explain the potential benefits of this treatment approach?",[28,112],"Smell Dysfunction",[114,115,116,117],"Olfactory dysfunction","Chronic rhinosinusitis","Steroid nasal drops","Olfactory cleft obstruction","2026-02-02",{"date":120,"type":37},"2026-02-04",{"date":122,"type":21},"2026-03-01",{"date":124,"type":21},"2028-12-31",{"name":126,"class":44},"Peking University Third Hospital",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":4},"100622421","phase-3-intra-sinus-povidone-iodine-and-budesonide-after-endoscopic-sinus-surgery-for-chronic-rhinosinusitis-100622421","NCT07383402","Intra-Sinus Povidone-Iodine and Budesonide After Endoscopic Sinus Surgery for Chronic Rhinosinusitis","The Efficacy of Intra-sinus Povidone-iodine\u002FBudesonide Gel Forming Suspension Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis: a Randomized, Double Blind, Placebo-controlled Trial","PVP-I","Inclusion Criteria:\n\nAge 19 years or older Scheduled for Endoscopic Sinus Surgery (ESS)\n\nExclusion Criteria:\n\nCystic fibrosis Systemic vasculitis Known or suspected hypersensitivity to povidone iodine Inhaled drug use (i.e., cocaine) in the preceding 6 months Nasal tumors Known or suspected immunodeficiencies Pregnant women Breast feeding women","19 Years",{"count":137,"type":21},180,[139],"PHASE3","Endoscopic sinus surgery (ESS) is commonly performed in patients with chronic rhinosinusitis (CRS) to improve sinus drainage and allow better delivery of topical therapies after surgery. Despite surgery, postoperative inflammation can persist and negatively affect healing and outcomes.\n\nThis randomized, double-blind, placebo-controlled clinical trial will evaluate whether intra-sinus administration of a gel-forming suspension containing povidone-iodine and budesonide improves postoperative endoscopic outcomes of the sinus cavities three months following ESS, compared with placebo.",[28],[143,144],"Povidone Iodine","Budesonide","2026-01-26",{"date":147,"type":37},"2026-02-03",{"date":149,"type":21},"2026-03-30",{"date":151,"type":21},"2028-01-01",{"name":153,"class":44},"Amin Javer",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":45},"100592709","phase-3-sinonasal-therapies-and-histologic-correlations-of-patients-with-cystic-fibrosis-in-the-era-of-highly-effective-modulator-therapy-100592709","NCT06996951","Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy","Sinonasal Therapies and Histologic Correlations for Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy","Inclusion Criteria:\n\n* Age 18 or older\n* Cystic Fibrosis diagnosis on HEMT\n* History of chronic rhinosinusitis\n* Using topical nasal irrigations +\u002F- additives (steroids, antibiotics)\n\nExclusion Criteria:\n\n* Below age of 18 years old\n* Cystic Fibrosis patient NOT on highly effective modulator therapy\n* Pregnant patients\n* Not currently using topical nasal irrigations +\u002F- additives (steroids, antibiotics)\n* History of sinonasal or nasopharyngeal tumors\n* Active sinonasal infection or pulmonary infection\n* Admission to hospital for pulmonary exacerbation within last 3 months\n* Oral antibiotics within last one month for upper respiratory or lower respiratory infection",{"count":162,"type":21},64,[139],"The investigators are doing this study to discover if it is appropriate for people with Cystic Fibrosis (CF) on highly effective modulator therapy (HEMT) to stop using certain standard Sino nasal therapies such as high-volume nasal saline irrigations, topical nasal steroids, and topical nasal antibiotics. They are also going to study the fluid inside the nose to see if there are changes when stopping these therapies. Right now, they are not sure if it is suggested to stop these treatments when patients begin highly effective modulator therapy (HEMT)",[166,28],"Cystic Fibrosis (CF)","2025-12-10",{"date":169,"type":37},"2025-12-16",{"date":171,"type":37},"2025-07-02",{"date":173,"type":21},"2026-07",{"name":175,"class":44},"Indiana University",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":192,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":45},"100615966","efficacy-of-lavender-aromatherapy-on-anxiety-and-pain-reduction-during-awake-otolaryngologic-procedures-100615966","NCT07299474","Efficacy of Lavender Aromatherapy on Anxiety and Pain Reduction During Awake Otolaryngologic Procedures","Efficacy Of Lavender Aromatherapy on Anxiety and Pain Reduction During Awake Otolaryngologic Procedures","Inclusion Criteria:\n\n* Adults ≥18 years old undergoing awake otolaryngologic procedures in the outpatient clinic\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Hypersensitivity to fragrances\n* Taking systemic NSAIDs or other systemic pain-relieving medications within 48 hours\n* Taking anxiolytics, hypnotics, sedating antihistamines, antidepressants on regular basis within 4 weeks\n* Pregnant or breastfeeding\n* Participation in another clinical research study within the prior 30 days",{"count":184,"type":21},184,[24],"The purpose of this study is to evaluate the efficacy of lavender aromatherapy in adult patients undergoing awake otolaryngologic procedures in the outpatient clinic setting. The main questions it aims to answer are:\n\n* Does lavender aromatherapy help reduce anxiety and\u002For pain, and improve patient comfort during awake otolaryngologic procedures in the clinic?\n* Do patients subjectively find aromatherapy relaxing and\u002For beneficial during the procedure?\n\nResearchers will compare lavender aromatherapy to placebo (an odorless liquid) to see if lavender aromatherapy helps improve patient comfort during their awake procedure\n\nParticipants will:\n\n* Have their scheduled procedure performed with lavender aromatherapy or placebo during the duration of the procedure\n* Take a short, less than 1 minute questionnaire both before and after the procedure, describing their levels of anxiety, pain and subjective impressions of the aromatherapy",[188,28,189,190,191],"Inferior Turbinate Hypertrophy","Rhinitis, Vasomotor","Thyroid Nodules","Vocal Fold Immobility",[193,194,195],"Aromatherapy","Otolaryngology","Awake procedure",{"date":197,"type":37},"2025-12-23",{"date":199,"type":21},"2025-12",{"date":201,"type":21},"2028-01",{"name":74,"class":44},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":211,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":231},"100613120","assessement-of-effectiveness-of-seawater-nasal-sprays-on-sinonasal-symptoms-100613120","NCT07262450","Assessement of Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms","Real-word Study to Assess Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms","SeaBridge","Inclusion criteria:\n\n* Subject's age and medical condition in compliance with the intended use and population\n* Subjects who, from the investigator's judgement, should benefit from nasal wash in accordance with routine medical practice\n* Subjects with at least two nasal symptoms of intensity ≥ 3 (6 modalities intensity SNOT-22 rating-scale) among the following:\n\n  * Nasal blockage\u002Fnasal congestion\u002F stuffy nose;\n  * Runny nose;\n  * Need to blow\u002Fclear the nose;\n  * Sneezing;\n  * Thick nasal discharge\u002Fsecretions;\n  * Decreased sense of smell \u002Ftaste (replaced by \"noisy breathing\u002Fmouth breathing\" for infants)\n* Subjects with impaired nasal breathing (score ≥ 3, 6-modalities intensity rating-scale), induced by the presence of nasal symptoms\n* For acute indications (only): subjects with symptoms started not later than 72 hours prior to enrolment (Day 0).\n* For allergic rhinitis indication: perennial allergic rhinitis with and without seasonal allergic rhinitis\n* For post-surgery indication: septoplasty and rhinoseptoplasty.\n* Subject\u002Fparent willing to perform nasal wash following advices received from HCPs.\n* Subjects (or parents for babies and children) agreeing to follow the study requirements during the whole study period (up to 3 months).\n* Subject (or parent for baby and children) able to understand verbal and written local language and in capacity to fill-in questionnaire by himself.\n* Subject having daily access to internet to answer online questionnaire.\n* Subject or Parent\u002Flegal guardian of the subject has given freely and expressly her\u002Fhis informed consent.\n* Subject affiliated to the health social security system or beneficiary of an equivalent system\n\nNon-inclusion criteria:\n\n* Subject with contraindications according to each IFU.\n* Hypersensitivity or known allergy to any component of the investigational products.\n* Subject taking part in another clinical study or being in the exclusion period of another clinical study.\n* Subject already using nasal wash to manage his nasal symptoms.\n* Subject already included once in the study.\n* Subject with a member of his household already included in the study if still in the follow-up phase.\n* Subject deprived of liberty by administrative or judicial decision or under legal guardianship.","15 Days",{"count":213,"type":21},1065,[24],"The purpose of this post-market clinical investigation is to assess in a real-life setting, the effectiveness, usage, tolerance, safety and satisfaction of 4 isotonic and hypertonic seawater-based CE-marked nasal sprays.\n\nThe main questions it aims to answer are:\n\n* Efficacy,\n* Safety,\n* Usage,\n* Satisfaction, in real-life usage among infants, children, adults and pregnant or breastfeeding women suffering from acute and chronic sinonasal pathologies. The 4 medical devices under investigation will be used in accordance with their intended use, target populations and medical indications.",[217,218,219,220,28,221],"URTI","Bronchiolitis","COVID - 19","Allergic Rhinitis","Post-surgery","2025-12-01",{"date":224,"type":37},"2025-12-03",{"date":226,"type":37},"2025-08-27",{"date":228,"type":21},"2026-08",{"name":230,"class":98},"Laboratoire de la Mer",32,{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":22,"phases":242,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":45},"100612896","phase-1-a-phase-i-study-evaluating-the-safety-tolerability-and-pharmacokinetics-of-vvn432-nasal-spray-100612896","NCT07259538","A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray","A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray in Healthy Chinese Adult Subjects and Patients With Chronic Rhinosinusitis.","Inclusion Criteria:\n\nPart 1:\n\n* Healthy male or female subjects aged 18 to 55 years old (inclusive);\n* Body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females; body mass index (BMI) within the range of 18.5 to 28.0 kg\u002Fm2 (inclusive);\n* No clinically significant abnormalities at screening or baseline.\n\nPart 2:\n\n* Male or female patients aged 18 to 55 years old (inclusive);\n* Clinically confirmed diagnosis of chronic rhinosinusitis with or without nasal polyps;\n* Presence of the following symptoms for \\>4 weeks before screening: nasal obstruction, mucous or mucopurulent rhinorrhea, facial pain\u002Fpressure, and reduced or lost sense of smell;\n* Modified Lund-Kennedy (MLK) score ≥ 2 in each nostril by nasal endoscopy;\n* Lund-Mackay score (LMK) ≥ 2 in each nostril by CT scan;\n* Nasal Construction Score (NCS) ≥ 2.\n\nExclusion Criteria:\n\nPart 1:\n\n* Known hypersensitivity or contraindications to the study drug or its components;\n* History or current conditions that affect the safety or absorption of the investigational drug;\n* History of drug abuse or drug dependence;\n* Participation in any other clinical trials and receiving an investigational drug within 12 weeks before screening or 5 half-lives, whichever is longer;\n* If female, is pregnant or lactating, or intends to become pregnant during the study period.\n\nPart 2:\n\n* Known hypersensitivity or contraindications to the study drug or its components;\n* Use of prohibited medications prior to screening and during the course of the study; History of drug abuse or drug dependence;\n* Participation in any other clinical trials and receiving an investigational drug within 12 weeks before screening or 5 half-lives, whichever is longer;\n* If female, is pregnant or lactating, or intends to become pregnant during the study period.","55 Years",{"count":241,"type":21},60,[243],"PHASE1","The goal of this clinical study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VVN432 Nasal Spray in healthy volunteers (Phase Ia) and in patients with chronic rhinosinusitis (Phase 1b).\n\nThis study consists of two parts (Phase 1a and Phase 1b):\n\nPhase 1a (SAD) is a single-center, randomized, double-masked, vehicle-controlled study to assess the safety, tolerability, and PK of VVN432 Nasal Spray in healthy adult subjects.\n\nPhase 1b (MAD) is a multi-center, randomized, double-masked, vehicle-controlled study to assess the safety, tolerability, PK\u002FPD, and preliminary efficacy of VVN432 Nasal Spray in patients with chronic rhinosinusitis.",[28],"2025-11-20",{"date":248,"type":37},"2025-12-02",{"date":250,"type":37},"2025-11-06",{"date":252,"type":21},"2026-11-30",{"name":254,"class":98},"VivaVision Biotech, Inc",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":45},"100596784","long-term-effect-of-dupilumab-in-n-erd-100596784","NCT07049978","Long-term Effect of Dupilumab in N-ERD","Long-term Effect of Dupilumab on Acetylsalicylic Acid (ASA) Intolerance and Its Mechanisms in Patients With Non-steroidal Anti-inflammatory Drug-exacerbated Respiratory Disease (N-ERD)","Inclusion Criteria:\n\n* Participated previously in our preliminary study (EK 1044\u002F2020) and continued Dupilumab treatment since then. Long-term use of Dupilumab since the preliminary study will be assessed based on patient self-report, as there is currently no clinical test or laboratory parameter available to objectively verify treatment duration.\n* Signed and dated informed consent has been obtained\n* Current therapy with Dupilumab\n\nExclusion Criteria:\n\n* Pregnancy (as determined by urine ß-HCG test)\n* Clinically significant abnormal laboratory values and active infection (Tbc, HIV, hepatitis A\u002FB\u002FC)\n* History of malignancy or immunodeficiency\n* Chronic obstructive lung disorders (COPD), other obstructive lung disorders (bronchiolitis)\n* Need for systemic corticosteroid therapy 1 month prior to screening visit\n* Eosinophilic pneumonia and Churg-Strauss Syndrome\n* Previous anaphylaxis and contraindications against ASA as outlined in the official prescribing information.",{"count":263,"type":21},30,"This prospective observational study investigates the long-term effects of Dupilumab in patients with NSAID-exacerbated respiratory disease (N-ERD). The study assesses changes in ASA tolerance, clinical parameters, inflammatory biomarkers, quality of life, and nasal microbiome during ongoing treatment with Dupilumab. All participants are receiving Dupilumab as part of standard clinical care.",[266,267,28,268,269],"NSAID-Induced Asthma","NSAIDs Hypersensitivity","Asthma Bronchiale","Nasal Polyposis","2025-07-03",{"date":272,"type":37},"2025-07-08",{"date":274,"type":21},"2025-07-01",{"date":276,"type":21},"2026-06-30",{"name":278,"class":44},"Medical University of Vienna",{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":287,"maxAge":4,"enrollmentInfo":288,"targetDuration":290,"studyType":84,"phases":4,"briefSummary":291,"conditions":292,"keywords":294,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":4},"100578739","the-german-national-crs-registry-genrecrs-clinical-evaluation-of-the-new-european-academy-for-allergy-and-clinical-immunology-eaaci-criteria-for-crswnp-disease-control-remission-and-cure-in-a-real-world-evidence-study-approach-100578739","NCT06815211","The German National CRS Registry (GenreCRS): Clinical Evaluation of the New European Academy for Allergy and Clinical Immunology (EAACI) Criteria for CRSwNP Disease Control, Remission and Cure in a Real-World Evidence Study Approach","A Prospective Study for Real-world Evaluation of the Novel European Academy for Allergy and Clinical Immunology (EAACI) Criteria for Disease Control, Remission and Cure in CRSwNP Utilizing the German National CRS Registry (GENRE CRS)","GenreCRS","Inclusion Criteria:\n\n* Patients above the age of 12 years\n* Patients who are diagnosed with CRS according to internationally valid guidelines (EPOS 2020)\n* Patients who provide written informed consent or by a legal representative\n\nExclusion Criteria:\n\n* Patients below the age of 12 years at initiation\n* Patients who do not provide written consent or withdraw their consent","12 Years",{"count":289,"type":21},500,"1 Year","The objective of the study is to establish a registry of patients diagnosed with Chronic Rhinosinusitis with and without Nasal Polyps (CRSwNP\u002FCRSsNP) to collect comprehensive longitudinal real-world evidence from specialised treatment centres in Germany. The primary analysis will concentrate on the treatment efficacy and safety of biologic drugs with a focus on defining disease Control, Remission, and Cure as well as to validate the corresponding clinical evaluation criteria.",[28,293],"Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps",[32,295,31,296,297],"CRSsNP","Registry","Patient Reported Outcome Measures (PROM)","2025-06-03",{"date":300,"type":37},"2025-06-04",{"date":302,"type":21},"2025-10",{"date":304,"type":21},"2028-10",{"name":306,"class":44},"Ärzteverband Deutscher Allergologen e.V.",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":17,"minAge":135,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":315,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":45},"100573747","phase-1-effectiveness-of-penthrox-vs-placebo-in-sinus-procedures-a-clinical-trial-100573747","NCT06750302","Effectiveness of Penthrox vs Placebo in Sinus Procedures, a Clinical Trial","The Effectiveness of Inhaled Methoxyflurane (Penthrox) vs Placebo for Pain Relief in Coblation and Sinus Procedures: a Double-blind, Randomized, Placebo - Controlled Trial","Inclusion Criteria:\n\n* Age 19 years or older\n* Scheduled for minor sinus surgery or coblation procedures\n\nExclusion Criteria:\n\n* Cystic fibrosis\n* Systemic vasculitis or other bleeding disorders\n* History of renal failure or severe kidney disease\n* History of liver failure or severe liver disease\n* Altered state of consciousness (head injury, alcohol use, drug use)\n* Known or suspected hypersensitivity to lidocaine or sensorcaine\n* Inhaled drug use (i.e., cocaine) in the preceding 6 months\n* Nasal tumors\n* Personal or family history of malignant hyperthermia\n* Respiratory depression",{"count":82,"type":21},[243,316],"PHASE2","The goal of this randomized controlled trial is to evaluate the effectiveness of inhaled methoxyflurane (Penthrox) as an analgesic for patients undergoing minor rhinology and sinus procedures, specifically comparing it to a placebo control. The primary question the study aims to answer is:\n\nDoes methoxyflurane provide superior pain relief compared to placebo during minor sinus procedures, as measured by the Visual Analog Scale (VAS)? If there is a comparison group: Researchers will compare the effects of Penthrox to the placebo (saline + one drop of methoxyflurane) to see if it provides better pain relief, reduces anxiety, and leads to fewer complications, including bleeding.\n\nParticipants will be asked to:\n\nInhale 3 mL of Penthrox or placebo during their procedure. Complete a VAS scale to assess pain. Complete anxiety assessments pre- and post-operatively. Be monitored for complications such as bleeding and other adverse effects. This study will help determine the effectiveness of Penthrox as a non-invasive, quick-acting analgesic for minor sinus surgeries.",[28],[28,320,321,322,323,324,325,326],"Sinus Surgery","Endoscopic Sinus Surgery (ESS)","Coblation","Methoxyflurane","Penthrox","Inhaled Analgesic","Inhaled Analgesics in Rhinology","2025-05-12",{"date":329,"type":37},"2025-05-15",{"date":331,"type":37},"2024-11-24",{"date":333,"type":21},"2026-06-24",{"name":335,"class":44},"St. Paul's Hospital, Canada",{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":17,"minAge":342,"maxAge":343,"enrollmentInfo":344,"targetDuration":4,"studyType":22,"phases":345,"briefSummary":346,"conditions":347,"keywords":348,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":45},"100589935","comparative-effects-of-therapeutic-ultrasound-and-sinus-massage-in-chronic-rhinosinusitis-a-randomized-controlled-study-100589935","NCT06960876","Comparative Effects of Therapeutic Ultrasound and Sinus Massage in Chronic Rhinosinusitis: a Randomized Controlled Study","Inclusion Criteria:\n\n* Age 20-60 years\n* Both gender\n* Diagnosed patients of chronic rhinosinusitis referred by an ENT specialist\n* According to the AAO-HNS, patients are diagnosed with CRS if they had:\n* Two or more major symptoms for ≥12 weeks. Or\n* one major symptom with two minor symptoms for ≥12 weeks (19) Major clinical symptoms\n* Pain or pressure on the face\n* Nasal congestion\n* Mucopurulent rhinorrhea either anteriorly, posteriorly, or both\n* Hyposmia\u002Fanosmia Minor clinical symptoms\n* Headache\n* Fever\n* Pain in the dental area\n* Halitosis\n* Pain or pressure on the ear\n* Cough\n\nExclusion Criteria:\n\n* Nasal polyps\n* Current Medical conditions in which ultrasound is contraindicated (20)\n* Facial metal implants\n* Face or head tumor\u002Fcyst\u002Fmalignancy\n* Deteriorated cognitive level\n* Previous surgery on the nose\n* Facial bone fracture\n* Reduced heat perception\n* Ischemic tissues\n* Skin allergies\u002Flesions to the face","20 Years","60 Years",{"count":241,"type":21},[24],"This is a randomized controlled trial. Previous studies show that both therapeutic ultrasound and sinus massage techniques have significant results in Chronic Rhinosinustis (CRS).\n\nHowever, there is no comparative study carried out between these two to show which technique has more effects in CRS.\n\nThis study will determine their comparative effects on:\n\n1. Pain measured on Numerical pain rating scale\n2. Sinonasal symptoms measured on sino-nasal outcome test questionaire\n3. Quality of life measured on rhinosinusitis disability index (RSDI)\n4. Nasal inspiratory airflow measured on peak nasal inspiratory flow meter. Participants of chronic rhinosinusitis will be selected according to the diagnostic criteria of American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) and will be randomly allocated into three groups. All three group will continue to receive medical intervention. Additionally one group will receive therapeutic ultrasound while other group will receive sinus massage. Whereas third group will be control group and won't receive any additional treatment.\n\nData will be collected at Foundation University College of Physical Therapy and Fauji Foundation Hospital.",[28],[349,350,351],"CHRONIC RHINOSINUSITIS","Therapeutic ultrasound","sinus massage","2025-04-29",{"date":354,"type":37},"2025-05-07",{"date":356,"type":37},"2024-07-18",{"date":358,"type":21},"2025-06-20",{"name":360,"class":44},"Foundation University Islamabad",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":368,"enrollmentInfo":369,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":371,"conditions":372,"keywords":373,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":45},"100580221","impact-of-structural-and-microenvironmental-abnormalities-in-olfactory-cleft-on-olfaction-in-crs-100580221","NCT06834477","Impact of Structural and Microenvironmental Abnormalities in Olfactory Cleft on Olfaction in CRS","The Influence of Structural and Microenvironmental Abnormalities in the Olfactory Cleft on Olfactory Function in Patients With Chronic Rhinosinusitis","Inclusion Criteria for patient group:\n\n1. Diagnosed with CRS based on the diagnostic criteria of the EPOS guideline.\n2. Provision of signed and dated informed consent form.\n3. Patients with CRS admitted to the hospital awaiting endoscopic sinus surgery.\n\nInclusion Criteria for control group:\n\n1. Healthy controls undergoing surgery for the deviated septum.\n2. Provision of signed and dated informed consent form.\n\nExclusion Criteria for patient group:\n\n1. Those who have taken oral glucocorticoids, antibiotics, anti-leukotrienes, and antihistamines within four weeks.\n2. Patients who have had prior sinus surgery.\n3. Patients with fungal sinusitis, inverted papilloma, or other nasal diseases.\n4. Patients with a diagnosis of immune suppression or suspicion of malignancy that may be affecting the nose\u002Fparanasal sinuses.\n5. Patients who are mentally or physically unable to perform olfactory tests\n\nExclusion Criteria for control group:\n\n1. Patients with nasal polyps, sinusitis, nasal cavity tumors and other diseases.\n2. Patients with hyposmia or anosmia.\n3. Patients with diagnosed neurodegenerative disease.\n4. Patients who are mentally or physically unable to perform olfactory tests.","80 Years",{"count":370,"type":21},80,"The purpose of this research is to investigate the impact of structural abnormalities and microenvironmental changes in the olfactory cleft on olfactory function in patients with chronic rhinosinusitis (CRS). It sought to elucidate the complex relationships among structural abnormalities, microenvironmental changes, and inflammatory factors contributing to olfactory dysfunction through a multidimensional assessment encompassing imaging, aerodynamics, biomarker , and histopathology analysis.",[28],[374,375],"olfactory cleft","olfactory dysfunction","2025-02-13",{"date":378,"type":37},"2025-02-19",{"date":380,"type":21},"2025-03-14",{"date":382,"type":21},"2027-03-14",{"name":126,"class":44},{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":392,"targetDuration":394,"studyType":84,"phases":4,"briefSummary":395,"conditions":396,"keywords":398,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":413},"100568594","real-life-evaluation-of-the-efficacy-of-biologicals-in-chronic-rhinosinusitis-with-nasal-polyposis-crswnp-100568594","NCT06683261","Real-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)","Real-life Evaluation of the Efficacy of Biologicals in CRSwNP","RELIBIO","Inclusion Criteria:\n\n1. Participant must be at least 18 years of age at the time of signing the informed consent.\n2. Capable of giving signed informed consent.\n3. Participants should have CRSwNP.\n4. Participants should fulfil the reimbursement criteria for their prescribed biological (omalizumab, mepolizumab and\u002For dupilumab).\n\nExclusion Criteria:\n\n1\\. Patients treated with other biological therapies in the 3 months prior to the current biological (this is not applicable to patients who are in the trial and switch biological).",{"count":393,"type":21},300,"3 Years","The goal of this observational study is to learn more about the real-world efficacy of biologics in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). All patients who are 18 years or older, who have CRSwNP and are eligible for reimbursement of a biological for the indication of CRSwNP can be included.\n\nThe main question is the efficacy of biologics in real life after 24 weeks. The main focus are patient reported outcomes measured via several questionnaires and the nasal polyp score, scored with nasal endoscopy.",[397,28],"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)",[399,32,400,401,402,403],"biologicals","real-world data study","mepolizumab","omalizumab","dupilumab","2024-11-07",{"date":406,"type":37},"2024-11-12",{"date":408,"type":37},"2022-09-23",{"date":410,"type":21},"2026-12",{"name":412,"class":44},"Universitaire Ziekenhuizen KU Leuven",8,{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":421,"targetDuration":4,"studyType":22,"phases":423,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":4},"100567510","xiangtong-tm-full-degradation-sinus-drug-stent-system-prospective-open-single-center-randomized-controlled-clinical-trial-100567510","NCT06669130","Xiangtong TM Full Degradation Sinus Drug Stent System Prospective, Open, Single-center, Randomized Controlled Clinical Trial","Efficacy and Safety of Xiangtong TM Full Degradation Sinus Drug Stent System","Inclusion Criteria:\n\n* Subjects are 18-65 years of age, male or non-pregnant female. The subject\u002Flegally authorized representative understands the purpose and procedures of the trial and voluntarily signs an informed consent form.\n\nSubjects must meet the diagnostic guidelines for chronic rhinosinusitis, have a confirmed diagnosis of bilateral chronic rhinosinusitis, and have a CT scan confirming bilateral Lund-Mackay scores \\>6 (CT scan within 3 months prior to surgery is valid).\n\n* Female subjects who are not breastfeeding at the time of the screening visit and who do not plan to breastfeed or become pregnant for up to one year after the starting point.\n* Subject has not participated in another clinical trial in the previous 3 months and agrees not to participate in another clinical trial until the endpoints of this trial have been met.\n\nExclusion Criteria:\n\n* Subject has a known allergic reaction or contraindication to the device material and its degradation products (mometasone acid, levulinic acid, racemic polylactic acid, propyl lactate, lactic acid).\n* The subject is on long-term oral hormonal medications.\n* The subject is receiving immunosuppressive therapy or has a known immunosuppressive or autoimmune disease: the subject has diabetes mellitus.\n* The subject has or has had glaucoma or high intraocular pressure.\n* The subject has cataracts.\n* The subject has an artificial eye.\n* Acute bacterial sinusitis and acute fungal sinusitis.\n* Subject has a life expectancy of less than 12 months.\n* Subject has participated in a clinical trial of another drug or device that did not meet the primary study endpoint: Subject is unable or unwilling to participate in this trial.",{"count":422,"type":21},50,[24],"Xiangtong® Fully Degradable Sinus Drug Stent System is a high-tech medical device independently developed by Puyi Bio, specially designed for patients with chronic rhinosinusitis (CRS) undergoing endoscopic sinus surgery (ESS).The product is implanted into the target site during and after surgery, which not only supports the separation of the wound and fixes the repaired mucosal flap, but also controls edema, prevents adhesions, maintains smooth drainage, and sustains the target site to fight against inflammation and promotes healing by means of slow-release hormones.",[28],"2024-10-30",{"date":428,"type":37},"2024-11-01",{"date":430,"type":21},"2024-12-01",{"date":432,"type":21},"2027-10-01",{"name":434,"class":44},"The First Affiliated Hospital with Nanjing Medical University",{"id":436,"slug":437,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":343,"enrollmentInfo":441,"targetDuration":4,"studyType":22,"phases":443,"briefSummary":444,"conditions":445,"keywords":449,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":4},"100567488","endoscopic-direct-draf-iia-carolyns-window-approach-versus-endoscopic-angled-draf-iiaapproach-in-chronic-rhinosinusitis-with-frontal-sinus-affection--a-comparative-study--100567488","NCT06668844","Endoscopic Direct \"Draf IIa\" (Carolyn's Window Approach) Versus Endoscopic Angled \"Draf IIa\"Approach in Chronic Rhinosinusitis With Frontal Sinus Affection ( A Comparative Study ).","Inclusion Criteria:\n\n1. Adult patients (aged 18 and above) with chronic rhino sinusitis affecting the frontal sinus with or without nasal polyps confirmed by nasal endoscopy and CT scan.\n2. Unilateral or bilateral cases.\n3. Denovo or recurrent cases.\n\nExclusion Criteria:\n\n1. Individuals younger than 18 year-old.\n2. Neoplasms",{"count":442,"type":21},68,[24],"Patients with chronic rhinosinusitis with frontal sinus affection indicated for sinuscopy will be randomly categorized in 2 groups: group A will have endoscopic directDraf IIa frontal sinusotomy and group B will have endoscopic angled Draf IIa frontal sinusotomy, the two groups will be compared according to ostium patency and perioperative morbidity",[28,446,447,448],"Frontal Sinusitis","Draf I or IIa","Functional Endoscopic Sinus Surgery (FESS)",[450,451,452],"Frontal sinusitis","Direct Draf","Endoscopic sinus surgery",{"date":454,"type":37},"2024-10-31",{"date":456,"type":21},"2025-01-01",{"date":458,"type":21},"2028-03-01",{"name":460,"class":44},"Assiut University"]